© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Email: info@future-science-group.com
Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle

News

June 06, 2017

Looking to the future of organs-on-chip

A new special issue from Future Science OA examines novel organ-on-a-chip research and provides expert insight into the future of the field.

 

It is well-accepted that 2D cell cultures are not fully reflective of the in vivo environment. This leads to issues translating research to the clinic. In a bid to overcome this, advances in lab-on-a-chip technology have begun to allow the development of platforms where cells, spheroids and tissue cultures can be cultured, thus allowing more accurate analysis and translation.

 

Organ-on-a-chip (OOAC) technology holds great potential in helping screen drugs in a more cost-effective manner, reducing failures, costs and pipeline time. Further potential advantages of OOAC technology going forward include a reduced need for animal models, and improved ability to personalize patient treatment.

 

The new special issue from Future Science OA sees Guest Editor John Greenman (University of Hull, UK) and an international group of experts discuss work at the forefront of OOAC research. “There are so many areas of biomedicine that require accurate and reproducible models of the human system,” commented Greenman. “The ability to keep organs in a functional state on chip, either alone or combined, will offer an ethically acceptable platform with real power to transform our understanding.”

 

The issue contains novel perspectives from across the multidisciplinary field, including both academics and those working in industry. In addition to in-depth discussion of various applications of OOAC including work on heart-on-a-chip, stem cells, spheroids and tissue biopsies, the issue presents new research into maintaining tumor biopsies and a survey evaluating end-user attitudes toward microfluidics-based cell culture.

 

“It has been a pleasure working with such a broad range of experts in the field to develop this timely special issue on OOAC,” commented Francesca Lake, Managing Editor of Future Science OA. “We hope the issue will stimulate further research into this up-and-coming field, and are excited to see what the future holds.”

 

The full issue is open access, and available at: http://www.future-science.com/toc/fso/3/2

 

The issue foreword is available from: http://www.future-science.com/doi/full/10.4155/fsoa-2017-0040.  An introductory video is available at: https://www.youtube.com/watch?v=yyAKF7bOQeA.

 

 

–END–

 

 

About Future Science OA
 

Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
 

 
About Future Science Group
 

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.